PMID- 35371056
OWN - NLM
STAT- MEDLINE
DCOM- 20220408
LR  - 20220525
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Evaluation of a Novel Adjuvanted Vaccine for Ultrashort Regimen Therapy of 
      Artemisia Pollen-Induced Allergic Bronchial Asthma in a Mouse Model.
PG  - 828690
LID - 10.3389/fimmu.2022.828690 [doi]
LID - 828690
AB  - Wormwood (Artemisia) pollen is among the top 10 aeroallergens globally that cause 
      allergic rhinitis and bronchial asthma. Allergen-specific immunotherapy (ASIT) is 
      the gold standard for treating patients with allergic rhinitis, conjunctivitis, 
      and asthma. A significant disadvantage of today's ASIT methods is the long 
      duration of therapy and multiplicity of allergen administrations. The goal of 
      this study was to undertake a pilot study in mice of a novel ultrashort vaccine 
      immunotherapy regimen incorporating various adjuvants to assess its ability to 
      treat allergic bronchial asthma caused by wormwood pollen. We evaluated in a 
      mouse model of wormwood pollen allergy candidates comprising recombinant Art v 1 
      wormwood pollen protein formulated with either newer (Advax, Advax-CpG, ISA-51) 
      or more traditional [aluminum hydroxide, squalene water emulsion (SWE)] adjuvants 
      administered by the intramuscular or subcutaneous route vs. intranasal 
      administration of a mucosal vaccine formulation using chitosan-mannose 
      nanoparticle entrapped with Art v 1 protein. The vaccine formulations were 
      administered to previously wormwood pollen-sensitized animals, four times at 
      weekly intervals. Desensitization was determined by measuring decreases in 
      immunoglobulin E (IgE), cellular immunity, ear swelling test, and pathological 
      changes in the lungs of animals after aeroallergen challenge. Art v 1 protein 
      formulation with Advax, Advax-CpG, SWE, or ISA-51 adjuvants induced a significant 
      decrease in both total and Art v 1-specific IgE with a concurrent increase in Art 
      v 1-specific IgG compared to the positive control group. There was a shift in 
      T-cell cytokine secretion toward a Th1 (Advax-CpG, ISA-51, and Advax) or a 
      balanced Th1/Th2 (SWE) pattern. Protection against lung inflammatory reaction 
      after challenge was seen with ISA-51, Advax, and SWE Art v 1 formulations. 
      Overall, the ISA-51-adjuvanted vaccine group induced the largest reduction of 
      allergic ear swelling and protection against type 2 and non-type 2 lung 
      inflammation in challenged animals. This pilot study shows the potential to 
      develop an ultrashort ASIT regimen for wormwood pollen-induced bronchial asthma 
      using appropriately adjuvanted recombinant Art v 1 protein. The data support 
      further preclinical studies with the ultimate goal of advancing this therapy to 
      human clinical trials.
CI  - Copyright (c) 2022 Tabynov, Babayeva, Nurpeisov, Fomin, Nurpeisov, Saltabayeva, 
      Renu, Renukaradhya, Petrovsky and Tabynov.
FAU - Tabynov, Kairat
AU  - Tabynov K
AD  - International Center for Vaccinology, Kazakh National Agrarian Research 
      University (KazNARU), Almaty, Kazakhstan.
AD  - Preclinical Research Laboratory With Vivarium, M. Aikimbayev National Research 
      Center for Especially Dangerous Infections, Almaty, Kazakhstan.
AD  - T&TvaX LLC, Almaty, Kazakhstan.
FAU - Babayeva, Meruert
AU  - Babayeva M
AD  - International Center for Vaccinology, Kazakh National Agrarian Research 
      University (KazNARU), Almaty, Kazakhstan.
AD  - Department of General Immunology, Asfendiyarov Kazakh National Medical University 
      (KazNMU), Almaty, Kazakhstan.
FAU - Nurpeisov, Tair
AU  - Nurpeisov T
AD  - Department of General Immunology, Asfendiyarov Kazakh National Medical University 
      (KazNMU), Almaty, Kazakhstan.
AD  - Republican Allergy Center, Research Institute of Cardiology and Internal 
      Medicine, Almaty, Kazakhstan.
FAU - Fomin, Gleb
AU  - Fomin G
AD  - International Center for Vaccinology, Kazakh National Agrarian Research 
      University (KazNARU), Almaty, Kazakhstan.
FAU - Nurpeisov, Temirzhan
AU  - Nurpeisov T
AD  - Department of General Immunology, Asfendiyarov Kazakh National Medical University 
      (KazNMU), Almaty, Kazakhstan.
FAU - Saltabayeva, Ulbossyn
AU  - Saltabayeva U
AD  - Nursing Department, Astana Medical University, Nur-Sultan, Kazakhstan.
FAU - Renu, Sankar
AU  - Renu S
AD  - Center for Food Animal Health, Ohio Agricultural Research and Development Center, 
      The Ohio State University (OSU), Wooster, OH, United States.
FAU - Renukaradhya, Gourapura J
AU  - Renukaradhya GJ
AD  - Center for Food Animal Health, Ohio Agricultural Research and Development Center, 
      The Ohio State University (OSU), Wooster, OH, United States.
FAU - Petrovsky, Nikolai
AU  - Petrovsky N
AD  - Vaxine Pty. Ltd., Flinders University, South Australia, Australia.
FAU - Tabynov, Kaissar
AU  - Tabynov K
AD  - International Center for Vaccinology, Kazakh National Agrarian Research 
      University (KazNARU), Almaty, Kazakhstan.
AD  - T&TvaX LLC, Almaty, Kazakhstan.
AD  - Republican Allergy Center, Research Institute of Cardiology and Internal 
      Medicine, Almaty, Kazakhstan.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220315
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Allergens)
RN  - 0 (Vaccines)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Allergens
MH  - Animals
MH  - *Artemisia
MH  - *Asthma
MH  - Disease Models, Animal
MH  - Humans
MH  - Immunoglobulin E
MH  - Mice
MH  - Pilot Projects
MH  - Pollen
MH  - *Rhinitis, Allergic
MH  - *Vaccines
PMC - PMC8965083
OTO - NOTNLM
OT  - Art v 1 protein
OT  - adjuvant
OT  - allergen-specific immunotherapy
OT  - allergy
OT  - mice
OT  - vaccine
OT  - wormwood pollen
COIS- KaissarT and KairatT are affiliated with T&TvaX. NP is affiliated with Vaxine, a 
      company holding rights to Advax and Advax-CpG adjuvants. The remaining authors 
      declare that the research was conducted in the absence of any commercial or 
      financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2022/04/05 06:00
MHDA- 2022/04/09 06:00
PMCR- 2022/01/01
CRDT- 2022/04/04 05:28
PHST- 2021/12/03 00:00 [received]
PHST- 2022/02/15 00:00 [accepted]
PHST- 2022/04/04 05:28 [entrez]
PHST- 2022/04/05 06:00 [pubmed]
PHST- 2022/04/09 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.828690 [doi]
PST - epublish
SO  - Front Immunol. 2022 Mar 15;13:828690. doi: 10.3389/fimmu.2022.828690. eCollection 
      2022.